Pharmaceutical intelligence for Jiangsu Hansoh Pharmaceutical Co., Ltd. with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalAugust 13, 2026

Phase 3 Study of HS-10380 Safety in Schizophrenia Patients Initiated by Jiangsu Hansoh

Jiangsu Hansoh Pharmaceutical Co., Ltd. has initiated a phase 3 open-label study to evaluate the long-term safety of HS-10380 in adult patients with schizophrenia in China.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalAugust 13, 2026

Phase 3 Study of HS-10380 Safety in Schizophrenia Patients Initiated by Jiangsu Hansoh

Jiangsu Hansoh Pharmaceutical Co., Ltd. has initiated a phase 3 open-label study to evaluate the long-term safety of HS-10380 in adult patients with schizophrenia in China.

Competitive activity

No signals indexed for this entity yet.

Assets

Phase →

Therapeutic areas

Neuroscience →

Schizophrenia →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.